Methods for modulating an immune response
AssigneeCue Biopharma, Inc.
InventorsRonald D. Seidel, III, Rodolfo J. Chaparro
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of modulating an immune response in an individual. The present disclosure provides methods of treatment. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) and an immune checkpoint inhibitor to an individual. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) to an individual who is undergoing treatment with immune checkpoint inhibitor.
Claims19
A method of treating an individual having a cancer that expresses a human papilloma virus-16 (HPV16) E7 antigen, the method comprising administering to the individual a combination of (i) an effective amount of an immune checkpoint inhibitor that is an anti-PD-1 antibody, and (ii) an effective amount of a protein that is a homodimer of two multimeric polypeptides, wherein each multimeric polypeptide comprises:
- a) a first polypeptide comprising:
- i) a peptide comprising an HPV16 E7 epitope;
- and
- ii) a β2-microglobulin (β2M) polypeptide;
- and
- b) a second polypeptide comprising:
- i) first and second variant IL-2 polypeptides, wherein the first and second variant IL-2 polypeptides each have the amino acid sequence set forth in SEQ ID NO:49;
- ii) a major histocompatibility complex (MHC) class I heavy chain polypeptide;
- and
- iii) an immunoglobulin (Ig) Fc polypeptide, and
- wherein the two multimeric polypeptides are joined to each other by one or more disulfide bonds that join the Ig Fc polypeptide of one multimeric polypeptide to the Ig Fc polypeptide of the other multimeric polypeptide, and
- wherein the immune checkpoint inhibitor and the protein are administered at the same time or at different times.
Dependencies are inferred from the claim text.